Loading
Life sciences · Journal article
International Journal of Drug Delivery Technology · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Premature ovarian insufficiency (POI) is an important reproductive and public health concern among women of reproductive age.Limited evidence is available regarding its epidemiological characteristics among women receiving COVID-19 booster vaccination, particularly in low-and middle-income countries.Objective: To determine the epidemiological characteristics and public health implications of premature ovarian insufficiency among married women younger than 40 years who received a COVID-19 booster vaccine.Methods: A hospital-based cross-sectional analytical study was conducted from January to June 2026 among married women aged 18-39 years attending the Department of Obstetrics and Gynecology.Demographic, reproductive, clinical, hormonal, and vaccination-related data were collected using a structured questionnaire and hospital records.Multivariable logistic regression was performed to identify factors independently associated with POI.Results: Among 332 participants, the illustrative prevalence of POI was 13.9%.Increasing age, family history of POI, and autoimmune disease were independently associated with POI (P < 0.05).Vaccination-related characteristics, including vaccine platform, previous COVID-19 infection, and the interval between booster vaccination and symptom onset, were not independently associated with POI after adjustment.Conclusion: POI was primarily associated with established demographic and clinical risk factors rather than vaccination-related characteristics.Continued reproductive health surveillance and prospective longitudinal studies are warranted to further clarify ovarian health following COVID-19 booster vaccination.